American Society of Clinical Oncology Annual Meeting

ASCO 2025

  1. Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559
  2. Actuate Therapeutics Announces Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
  3. Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug)
  4. Affimed N.V. announced abstract on Ph 2 LuminICE-203 study of acimtamig + AlloNK® (AB-101) and two abstracts on AFM24 + atezolizumab in NSCLC
  5. Alligator Bioscience Presents OPTIMIZE-1 Biomarker Data
  6. Allogene Therapeutics Announces Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
  7. Antengene to Present Clinical Results from 2 Studies in CPI-resistant Solid Tumors
  8. Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Trial
  9. Arcus Biosciences to Present First Combination Data for Casdatifan + Cabozantinib in an Oral Presentation
  10. Arvinas Announces Results from the VERITAC-2 Trial for Oral Presentation
  11. Ascentage Pharma Announces Clinical Data of Lisaftoclax in Venetoclax-Refractory Patients
  12. Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term OS in Metastatic HSPC
  13. AstraZeneca to present 80 abstracts from 20 approved and potential new medicines
  14. Bantam Pharmaceutical to Present poster to ongoing Ph 1 trial  of BTM-3566 in patients with R/R mature B-cell lymphomas
  15. Beigene to share 23 abstracts featuring new data across its hematology and solid tumor portfolio
  16. Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Ph 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC
  17. Bicycle Therapeutics Announces Poster Presentations 
  18. BioAtla Announces Poster Presentation from Ph 2 trial of ozuriftamab vedotin (BA3021) in patients with heavily pretreated SCCHN
  19. BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data 
  20. Candel Therapeutics Presents Positive Ph 3 CAN-2409 Results in Localized Prostate Cancer
  21. CARsgen to present Satri-cel data
  22. CCM Biosciences announces the presentation of its next-gen FLT3 inhibitor drug program for AML
  23. Corcept To Present Data From Pivotal Ph 3 Rosella Trial Of Relacorilant In Platinum-resistant Ovarian Cancer
  24. Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Ph 2b REZILIENT1 Trial of Zipalertinib
  25. Daiichi Sankyo to present new clinical research across oncology portfolio with more than 20 abstracts in multiple cancers
  26. Eli Lilly announced data from studies of imlunestrant, olomorasib, LY4170156, and Verzenio
  27. Eisai to present clinical research across its oncology portfolio and pipeline
  28. Exelixis Announces Results from Ph 1b/2 STELLAR-002 Trial of Zanzalintinib + Immune Checkpoint Inhibitors in Advanced Kidney Cancer 
  29. FORE Biotherapeutics to Present Plixorafenib Abstract
  30. Foundation Medicine to Present Over 15 Abstracts 
  31. Genmab to Highlight New Data Evaluating Rina-S and epcoritamab
  32. GV20 Therapeutics to Present Updated Ph 1 Monotherapy Data on GV20-0251
  33. HUTCHMED presents data of several assets including savolitinib, ranosidenib, fruquintinib, and surufatinib
  34. ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy 
  35. ImPact Biotech Announces Late-Breaking Podium Presentation Highlighting ENLIGHTED Study Interim Analysis
  36. IMUNON Announces Oral Presentation Highlighting Survival Data from Ph 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
  37. Iovance Announces 5-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma
  38. Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib
  39. Menarini Group Presents Updated Data of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC)
  40. Merck announced the presentation of new oncology data across more than 12 tumor types
  41. Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations 
  42. Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
  43. Mythic Therapeutics to Present Efficacy Data from Ph 1 KisMET-01 Study of MYTX-011 in NSCLC
  44. Novita Pharmaceuticals Announces Oral Presentation of Ph 2 NP-G2-044 Data
  45. Novocure to Present Results from the Ph 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
  46. Nuvalent to Present Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 
  47. Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive NSCLC
  48. Obsidian Therapeutics to Present Clinical Data from OBX-115 for Patients with Advanced Melanoma in Oral Presentation
  49. Oncolytics Biotech® to Present New Clinical Trial Data Showing Pelareorep’s Immune Activation Capabilities
  50. OSE Immunotherapeutics and Boehringer Ingelheim to Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity in 2 Ongoing Trials
  51. PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV
  52. Pfizer to present more than 60 abstracts, including 15 oral and rapid oral presentations to highlight advancements across oncology portfolio
  53. Rakuten Medical Announces Trial in Progress Poster Presentation and Enrollment Expansion to Taiwan for Global Ph 3 ASP-1929-381
  54. Regeneron announces Initial Results from Linvoseltamab + Carfilzomib/Bortezomib in Earlier Lines of Treatment for R/R Multiple Myeloma
  55. Rigel Announces Poster Presentations from the GAVRETO® (pralsetinib) Ph 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors and supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML
  56. Sapience Therapeutics Announces Oral Presentation of Lucicebtide Ph 2 Results
  57. Servier announces Presentations in IDH-Mutated Cancers
  58. Syncromune Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Ph 1 Data for Metastatic Prostate Cancer
  59. Transgene to Present 24-month Disease-Free Survival Data from All Patients in Ph I Part of Trial of TG4050
  60. Verastem Oncology to present the updated RAMP 205 data as well as updated data on VS-7375
  61. Verismo Therapeutics to present overview of ongoing STAR-101 Ph 1 clinical study
  62. Volastra Announces Initial Data from First-in-Human Ph 1/2 Trial of VLS-1488
  63. Xilio Therapeutics to Present Updated Ph 2 Data for Vilastobart in Combination with Atezolizumab in Patients with MSS CRC
  64. Zai Lab to Present Data from Ph 1 Trial of ZL-1310
  65. Zentalis Pharmaceuticals to present Ph 1/2 trial of azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant CRC
  66. Zymeworks Inc. announced multiple presentations related to oncology programs

Share:

Read more